Ryan Chow
About
Research
Publications
2025
Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering
Tang K, Zhou L, Tian X, Fang S, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Kim H, Luo Z, Xin S, Lin S, Park D, Yang L, Zhang Y, Suzuki K, Majety M, Ling X, Lam S, Chow R, Ren P, Tao B, Li K, Codina A, Dai X, Shang X, Bai S, Nottoli T, Levchenko A, Booth C, Liu C, Fan R, Dong M, Zhou X, Chen S. Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering. Nature Biomedical Engineering 2025, 9: 1290-1308. PMID: 40114032, PMCID: PMC12360953, DOI: 10.1038/s41551-025-01371-2.Peer-Reviewed Original ResearchKnock-In MiceBone marrow-derived dendritic cellsCD8+ T cellsNon-viral delivery vehiclesAdeno-associated virusDisease modelsCD4+Dendritic cellsC57BL/6 backgroundT cellsConstitutive expressionB cellsLipid nanoparticlesEx vivoGenome editingMiceMultiplex genome engineeringROSA26 locusGene interaction networksMultiplex genome editingLiver tissueTargeted genome editingDiseaseDelivery vehiclesCRISPR RNAAuthor Correction: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy
Zhang F, Chow R, He E, Dong C, Xin S, Mirza D, Feng Y, Tian X, Verma N, Majety M, Zhang Y, Wang G, Chen S. Author Correction: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy. Nature Biotechnology 2025, 43: 2068-2068. PMID: 39901026, DOI: 10.1038/s41587-025-02576-1.Peer-Reviewed Original ResearchMultiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy
Zhang F, Chow R, He E, Dong C, Xin S, Mirza D, Feng Y, Tian X, Verma N, Majety M, Zhang Y, Wang G, Chen S. Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy. Nature Biotechnology 2025, 43: 2054-2067. PMID: 39820813, DOI: 10.1038/s41587-024-02535-2.Peer-Reviewed Original ResearchAdeno-associated virusTumor microenvironmentImmunosuppressive genesAntitumor efficacyCD8+ T cell infiltrationIn vivo antitumor efficacyCombinatorial cancer immunotherapyImmunosuppressive tumor microenvironmentSyngeneic tumor modelsT cell infiltrationTumor microenvironment remodelingMulti-agent combinationsMultiple tumor typesAntitumor immunityCombinatorial immunotherapyOptimal immunotherapyCancer immunotherapyGene alterationsTumor typesTumor modelReduced neutrophilLiver toxicityShRNA treatmentWhole-transcriptome profilingImmunotherapy
2024
65 High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogenetics
Tang K, Zhou X, Fang S, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Xin S, Zhou L, Lin S, Majety M, Lin X, Lam S, Chow R, Bai S, Nottoli T, Booth C, Liu C, Dong M, Chen S. 65 High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogenetics. 2024, a72-a72. DOI: 10.1136/jitc-2024-sitc2024.0065.Peer-Reviewed Original ResearchIn vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy
Peng L, Renauer P, Sferruzza G, Yang L, Zou Y, Fang Z, Park J, Chow R, Zhang Y, Lin Q, Bai M, Sanchez A, Zhang Y, Lam S, Ye L, Chen S. In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy. Nature Biotechnology 2024, 43: 752-761. PMID: 38918616, PMCID: PMC11668911, DOI: 10.1038/s41587-024-02282-4.Peer-Reviewed Original ResearchPrimary NK cellsTumor-infiltrating NKCAR-NK cellsNK cellsGenetic checkpointsNatural killerChimeric antigen receptor (CAR)-NK cellsHuman primary NK cellsSolid tumor mouse modelNK cell-based immunotherapyIn vivo antitumor efficacyCAR-NK therapyNK cell therapyCell-based immunotherapyNK cell functionTumor mouse modelTumor infiltrationAntitumor efficacyCell therapyCytokine productionEnhanced cytotoxicityMouse modelSingle-cell transcriptomic landscapeClinical potentialCell function
2023
DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner
Strine M, Cai W, Wei J, Alfajaro M, Filler R, Biering S, Sarnik S, Chow R, Patil A, Cervantes K, Collings C, DeWeirdt P, Hanna R, Schofield K, Hulme C, Konermann S, Doench J, Hsu P, Kadoch C, Yan Q, Wilen C. DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner. PLOS Biology 2023, 21: e3002097. PMID: 37310920, PMCID: PMC10263356, DOI: 10.1371/journal.pbio.3002097.Peer-Reviewed Original ResearchConceptsGenome-wide CRISPR/Cas9 screenCRISPR/Cas9 screenPathogenic human coronavirusesKinase-independent mannerRegulated kinase 1AProviral host factorNovel drug targetsMultiple cell typesDNA accessibilityHost factorsKinase functionHuman coronavirusesHost genesDistal enhancerNovel regulatorCas9 screenKinase 1AGene expressionNeuronal developmentDYRK1ADrug targetsDiverse coronavirusesProviral activityCell typesSevere acute respiratory syndrome coronavirus 2Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.Peer-Reviewed Original ResearchConceptsOral anticancer agentsTherapy utilizationMedicare beneficiariesNon-Hispanic white raceMetastatic renal cell carcinomaNon-Hispanic black raceOlder US patientsUS Medicare beneficiariesRenal cell carcinomaLogistic regression modelsTherapy receiptMultivariable adjustmentSystemic therapyMale sexUS patientsCell carcinomaStudy criteriaBlack raceFemale sexPatient raceWhite raceImmunotherapyOutcomes persistSexPatientsMutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade
Song E, Chow R. Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade. Cancer Cell 2023, 41: 651-652. PMID: 36931275, DOI: 10.1016/j.ccell.2023.02.013.Peer-Reviewed Original ResearchConceptsEnhanced anti-tumor immunityImmune checkpoint blockade therapyTumor-intrinsic mutationsAnti-tumor immunityImmune checkpoint blockadeCheckpoint blockade therapyBlockade therapyCheckpoint blockadeCo-culture systemImmune resistanceIFNSuch alterationsPatientsBlockadeTherapyTumorsChowCancerMutationsImmunityEvolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma.
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Evolution of systemic therapy from 2015 to 2019 for older patients in the United States with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2023, 41: 610-610. DOI: 10.1200/jco.2023.41.6_suppl.610.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsOral anti-cancer agentsNon-Hispanic white patientsSystemic therapyRenal cell carcinomaNHW patientsWhite patientsCell carcinomaMedicare beneficiariesService Medicare Parts ARetrospective cohort studyOverall treatment rateMedicare Part AIO therapyMRCC therapyAnti-cancer agentsCheckpoint inhibitorsCohort studyOlder patientsRandomized trialsSurvival improvementFirst therapyStudy criteriaTreatment receiptIL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies
Chen J, Murphy M, Singh K, Wang A, Chow R, Kim R, Cohen J, Ko C, Damsky W. IL17A mRNA Staining Distinguishes Palmoplantar Psoriasis from Hyperkeratotic Palmoplantar Eczema in Diagnostic Skin Biopsies. JID Innovations 2023, 3: 100189. PMID: 37205304, PMCID: PMC10186614, DOI: 10.1016/j.xjidi.2023.100189.Peer-Reviewed Original ResearchMycosis fungoides palmaris et plantarisPalmoplantar psoriasisNonacral sitesPalmoplantar eczemaMRNA expressionAcral skinIL-13 expressionPalmaris et plantarisDiagnostic skin biopsyDermatopathology databaseIL-17AHistopathologic featuresClinical managementBiopsy specimensSkin biopsiesCytokine biomarkersUseful biomarkerEczemaPsoriasisDiagnostic clarityMRNA stainingDermatosesBiomarkersSitu hybridizationSkin
Academic Achievements & Community Involvement
News & Links
News
- November 28, 2022
Multidisciplinary COPPER Center Brings a Public Health Lens to Cancer Care
- November 01, 2022Source: Yale News
Why Immunotherapy Works Well for Some Cancer Patients, but Not Others
- October 27, 2022
New Findings on Endometrial Cancer Treated With Pembrolizumab
- October 27, 2022Source: Yale News
Why Immunotherapy Works Well For Some Cancer Patients, But Not Others